← All trials
NCT04838795
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 18, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Apr 9, 2021
- Last posted
- Oct 18, 2021
- Enrollment
- 500000
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- Wits Health Consortium (Pty) LtdLead sponsor
- University of WashingtonCollaborator
- Janssen Pharmaceutica NVCollaborator
- BiocairCollaborator
- BioVacCollaborator
- Dis-Chem PharmacyCollaborator
- Hutchinson Center Research Institute of South Africa (HCRISA)Collaborator
- KwaZulu-Natal Research Innovation and Sequencing Platform - KRISPCollaborator
- government of south africaCollaborator
- Bio Analytical Research CorporationCollaborator
- National Institute for Communicable Diseases, South AfricaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.